Cancer Stem Cell-Specific Molecule EP3603671A2, Chugai, Apr 15
Summary
The European Patent Office published patent application EP3603671A2 by Chugai Seiyaku Kabushiki Kaisha on April 15, 2026, covering cancer stem cell-specific molecules including antibodies, compositions, and methods for cancer detection and treatment. The application is published under the A2 designation, indicating international application with international search report. Designated states cover all current EPO member states and extension states across Europe.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
The European Patent Office published patent application EP3603671A2 for cancer stem cell-specific molecules, filed by Chugai Seiyaku Kabushiki Kaisha. The application covers therapeutic antibodies, compositions, and diagnostic methods targeting cancer stem cells. The A2 publication kind indicates an international application with international search report.
Competitors in the cancer therapeutics and diagnostics space should monitor this application for freedom-to-operate implications. The designated states cover all current EPO member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CANCER STEM CELL-SPECIFIC MOLECULE
Publication EP3603671A2 Kind: A2 Apr 15, 2026
Applicants
Chugai Seiyaku Kabushiki Kaisha
Inventors
YAMAZAKI, Tatsumi, OKABE, Hisafumi, KOBAYASHI, Shinta, WATANABE, Takeshi, MATSUBARA, Koichi, NATORI, Osamu, KATO, Atsuhiko, SUZUKI, Masami
IPC Classifications
A61K 39/395 20060101AFI20251007BHEP A61K 39/39 20060101ALI20251007BHEP C12Q 1/68 20180101ALI20251007BHEP G01N 33/15 20060101ALI20251007BHEP G01N 33/50 20060101ALI20251007BHEP G01N 33/574 20060101ALI20251007BHEP C07K 14/51 20060101ALI20251007BHEP C07K 16/30 20060101ALI20251007BHEP C12Q 1/6886 20180101ALI20251007BHEP A61P 1/04 20060101ALI20251007BHEP A61P 35/00 20060101ALI20251007BHEP A61P 35/04 20060101ALI20251007BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.